A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to compare the efficacy and safety of aripiprazole with placebo in the treatment of alcoholics. In this 12-week multicenter, double-blind study, 295 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition alcohol dependence were randomized to treatment with aripiprazole (initiated at 2 mg/d, titrated to a maximum dose of 30 mg/d at day 28) or placebo after screening, wherein patients maintained alcohol abstinence for 3 days or more. The primary efficacy measure was the percentage of days abstinent over 12 weeks. Discontinuations (40.3% vs 26.7%) and treatment-related adverse events (82.8% vs 63.6%) were higher with aripiprazole than with placebo. Mean percentage of days abstinent was similar between aripiprazole and placebo (58.7% vs 63.3%; P = 0.227). Percentage of subjects without a heavy drinking day and the time to first drinking day were also comparable between groups, although the aripiprazole group had fewer drinks per drinking day (4.4 vs 5.5 drinks; P < 0.001). The aripiprazole group showed a larger decrease in percent carbohydrate-deficient transferrin, a biomarker of heavy alcohol consumption at weeks 4 (-14.91% vs -2.23%; P = 0.020) and 8 (-16.92% vs -5.33%; P = 0.021), although not at week 12 (-9.06% vs -4.12%; P = 0.298). At study end point, aripiprazole-treated subjects reported more positive subjective treatment effects and less overall severity of alcohol dependence than placebo-treated subjects. Although there was no difference between aripiprazole and placebo on the primary end point, possibly because of dose-related attrition, effects on the secondary outcomes suggest that further study of aripiprazole for treatment of alcohol dependence may be warranted at lower doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 2×
“Subjects also had to have a score of less than 8 on the Clinical Institute Withdrawal Assessment for Alcohol Revised.17 Subjects with substance abuse or dependence (on drugs other than cocaine and opioids and with the exception of marijuana abuse) within the past 12 months were excluded.”
Method(1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.7 · Cited by 1,905
Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction
Koob, G. F., & Le Moal, M. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1442 · Cited by 963
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“For example, antagonising dopaminergic activity with newer generation antipsychotics such as aripiprazole has shown some limited efficacy (Anton et al., 2008; Martinotti et al., 2009).”
BackgroundTime to connect: bringing social context into addiction neuroscience
Heilig, M., Epstein, D. H., Nader, M. A., & Shaham, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.67 · Cited by 298
The dopamine hypothesis of drug addiction and its potential therapeutic value
Diana, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00064 · Cited by 251
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Another multicenter RCT enrolling 295 participants over 12 weeks found no significant difference between the aripiprazole and placebo groups in percentage of participants completely abstinent from alcohol throughout the study or time to first drinking day; however, the average number of drinks per drinking day was sig…”
BackgroundMedication treatment of different types of alcoholism
Johnson, B. A. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.08101500 · Cited by 151
Metadata
- Authors
- Anton, R. F., Kranzler, H., Breder, C., Marcus, R. N., Carson, W. H., & Han, J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-02
- Volume
- 28
- Issue
- 1
- Pages
- 5-12
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2076390838
- Cited by
- 106
- References
- 4
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181602fd4
- The paper
- Anton, R. F., Kranzler, H., Breder, C., Marcus, R. N., Carson, W. H., & Han, J. (2008). A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181602fd4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.